Type 1 lipoteichoic acid (LTA) is present in many clinically important gram-positive bacteria, including enterococci, streptococci, and staphylococci, and antibodies against LTA have been shown to opsonize nonencapsulated Enterococcus faecalis strains. In the present study, we show that antibodies against E. faecalis LTA also bind to type 1 LTA from other gram-positive species and opsonized Staphylocccus epidermidis and Staphylcoccus aureus strains as well as group B streptococci. Inhibition studies using teichoic acid oligomers indicated that cross-reactive opsonic antibodies bind to the teichoic acid backbone. Passive immunization with rabbit antibodies against E. faecalis LTA promoted the clearance of bacteremia by E. faecalis and S. epidermidis in mice. Furthermore, passive protection also reduced mortality in a murine S. aureus peritonitis model. The effectiveness of rabbit antibody against LTA suggests that this conserved bacterial structure could function as a single vaccine antigen that targets multiple gram-positive pathogens.
Type 1 lipoteichoic acid (LTA) is present in many clinically important gram-positive bacteria, including enterococci, streptococci, and staphylococci, and antibodies against LTA have been shown to opsonize nonencapsulated Enterococcus faecalis strains. In the present study, we show that antibodies against E. faecalis LTA also bind to type 1 LTA from other gram-positive species and opsonized Staphylocccus epidermidis and Staphylcoccus aureus strains as well as group B streptococci. Inhibition studies using teichoic acid oligomers indicated that cross-reactive opsonic antibodies bind to the teichoic acid backbone. Passive immunization with rabbit antibodies against E. faecalis LTA promoted the clearance of bacteremia by E. faecalis and S. epidermidis in mice. Furthermore, passive protection also reduced mortality in a murine S. aureus peritonitis model. The effectiveness of rabbit antibody against LTA suggests that this conserved bacterial structure could function as a single vaccine antigen that targets multiple gram-positive pathogens.
Bacterial pathogens usually display a diverse set of cellsurface antigens that help them to escape the adaptive immune system. Due to the lack of bacterial antigens that are conserved across species, separate antigens are used against each pathogen, resulting in the necessity of administering a large number of vaccines to achieve broad coverage against several pathogens. Prior studies have shown that nonencapsulated Enterococcus faecalis strains, which represent approximately half of all clinical isolates, are opsonized by antibodies directed against lipoteichoic acid (LTA) [1] [2] [3] and that active and passive immunization using LTA protects against E. faecalis and Enterococcus faecium bacteremia [4] .
LTA is an amphiphilic molecule consisting of a glycolipid anchor, which is inserted into the cell membrane, and a polyalditolphosphate chain [5, 6] . In the majority of gram-positive bacteria, LTA is composed of poly-1,3-(glycerolphosphate), nonstoichiometrically decorated at the C-2 hydroxyl of glycerol with hydrogen, D-alanine, mono-or oligoaccharides [5] . This type of LTA is also called type 1 LTA according to the classification of Fischer [7, 8] . In E. faecalis, the C-2 hydroxyl is glycosylated either by kojibiose (a-Dglucopyranosyl-(1/2)-a-D-glucose) or 6,6#-di-alanyla-kojibiose [2] . LTA from Staphylococcus aureus and Staphylococcus epidermidis is partially substituted at the C-2 hydroxyl with a-D-GlcNAc, whereas in group B streptococci, the C-2 hydroxyl of glycerol is not glycosylated [9, 10] . Because type 1 LTA is expressed by a range of clinically relevant gram-positive bacteria including staphylococci, enterococci, and some streptococci and is essential for the integrity of the cell envelope, it may be a promising target for vaccine development [6, 11] . In the current study, we analyzed cross-reactivity and specificity of rabbit antibodies raised against E. faecalis LTA, defined the structural requirements for binding of opsonic antibodies to this antigen, and evaluated the protective efficacy of antibodies to LTA against infection with E. faecalis, S. epidermidis, and S. aureus.
METHODS

Bacterial Strains and Culture Conditions
Bacterial strains used in this study are listed in Table 1 . For purification of LTA, bacteria were grown at 37°C with shaking in tryptic soy broth (TSB; CASO-broth; Merck). After 18 hours of culture, bacteria were harvested by centrifugation and washed twice in 0.1 mol/L citrate buffer pH 4.6.
Purification and Biochemical Characterization of LTAs
LTAs from E. faecalis, E. faecium, Enterococcus hirae, group B streptococci (GBS), S. epidermidis, and S. aureus were obtained by butanol extraction as described elsewhere [2] . Protein content of LTA preparations was quantified by Bradford assay. In addition, LTA preparations were analyzed for contaminating proteins, DNA, or carbohydrates by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in gradient gels containing acrylamide (4/12% wt/vol, Invitrogen) and stained with Coomassie blue and Stains All [25] . Purity of LTA preparations was also assessed by 1 H-NMR spectrometry as described elsewhere [2] .
Rabbit Immunization
Rabbit antibodies to LTA from E. faecalis 12030 (anti-LTA EF) have been described elsewhere [3] . A second rabbit was immunized with LTA from GBS strain NEM 316 using the same protocol using complete and incomplete Freund adjuvant (anti-LTA-GBS). All serum samples were heat-inactivated at 65°C for 30 minutes to reduce complement activity. By Western blot analysis with whole cell lysates of the vaccine strain, the antiserum was monospecific to LTA from GBS. Serum from a rabbit immunized with seaweed alginate according to the same vaccination protocol was used as control in the passive protection and opsonophagocytic killing experiments [26] . For all experiments, serum from the final bleed of the rabbit was used.
Enzyme-Linked Immunosorbent Assay Studies
Standard protocols were applied in enzyme-linked immunosorbent assay (ELISA) experiments [2] . For inhibition ELISAs, 2-fold dilutions of inhibiting polysaccharide starting at 100 lg/mL (final concentration) were mixed with a single dilution of rabbit antiserum (1:3200), previously shown by ELISA to be near the middle of the linear portion of the binding curve.
Opsonophagocytic Assays
An opsonophagocytic assay was used as previously described [2, 27] . Highly purified LTA or synthetic teichoic acid (TA) mimetics were used as inhibitor. Serum against LTA from E. faecalis 12030 was diluted to a concentration of 1:800 (final concentration) to give 70%-80% killing in the opsonophagocytic killing assay. This antiserum was incubated at 4°C for 60 minutes with 0.08-100 lg/mL of inhibitor. After this incubation step, the opsonic killing assay was continued as described above. The percentage of inhibition of killing was calculated by determining the ratio of the CFUs surviving in the tubes with inhibitor to the CFUs surviving in the tubes without inhibitor.
Protection Studies
Passive protection by rabbit anti-LTA was evaluated in a mouse bacteremia model as described elsewhere [4] with some modifications. Eight female Balb-C mice 6-8 weeks old were immunized intraperitoneally with 0.2 mL anti-LTA-EF, rabbit serum raised against a alginate-bovine serum albumin (BSA) conjugate vaccine (anti-Alg), or heat-inactivated rabbit serum from nonimmune rabbits 3-4 weeks old 24 hours before challenge. Mice were infected by intravenous injection of E. faecalis 12030 (7.2 3 10 8 bacteria per mouse) or S. epidermidis M187 (7.0 3 10 8 ) via the tail vein. All bacterial inocula were grown overnight in TSB and adjusted to the correct concentration in phosphate-buffered saline (PBS). Twenty-four hours after infection, mice were killed and exsanguinated, and bacterial counts in the blood were enumerated by serial dilutions. For the peritonitis model, 7 or 8 female Balb-C mice 6-8 weeks old were passively immunized as described above and injected intraperitoneally 24 hours later with S. aureus strains (S. aureus Newman 5.6 3 10 8 , S. aureus SA 113 5.0 3 10 8 , and S. aureus ATCC 43300 1.0 3 10 10 bacteria per mouse) in 0.2 mL PBS [27] [28] [29] . Mice were monitored twice daily for mortality or signs of illness for a period of 7 days.
Statistical Analysis
Statistical significance for 2-way comparisons was determined by an unpaired t test. Analysis of variance for multigroup comparisons was used on log-transformed data, and the Tukey multiple-comparison test was used for post hoc analysis for pairwise comparisons. Survival data were compared using the log-rank (Mantel-Cox) test. A P value ,.05 was considered statistically significant.
Ethics Statement
All animal experiments were performed in compliance with national guidelines and were approved by local institutional committees. The institutional review board of the University of Freiburg approved the study protocol, and written informed consent was obtained from all study participants.
RESULTS
Production of Antisera
Rabbit antiserum against LTA from E. faecalis strain 12030 was generated as described elsewhere [3] . In addition, we prepared a second rabbit antiserum against LTA purified from GBS NEM 316. LTA preparations used as vaccine antigens were purified according to the method described by Morath et al [10] . The purified carbohydrate contained ,1% protein, and the presence of other contaminating polysaccharides was excluded by 1 H nuclear magnetic resonance (NMR) analysis. Purity of the vaccine preparations was also confirmed by SDS-PAGE and staining with Coomassie (proteins), and Stains All (proteins, nucleic acids, carbohydrates). Western blot analysis of the antiserum with whole cell lysates of the vaccine strain as antigen revealed a single, broad band around 15 kDa, indicative of LTA. To control for nonspecific antibodies induced by the vaccination protocol, a third rabbit was vaccinated with an irrelevant antigen (seaweed alginate conjugated to BSA) using the same adjuvant [26] .
Binding of Antibodies Against E. faecalis LTA to Heterologous LTA
To determine whether type 1 LTA from other gram-positive bacteria is recognized by antibodies against E. faecalis LTA, we measured the binding of rabbit antibodies raised against E. faecalis LTA (LTA-EF) to several LTA preparations purified from enterococcal strains, GBS, S. aureus, and S. epidermidis by direct ELISA ( Figure 1A) . Surprisingly, antibodies to LTA-EF bound somewhat better to heterologous LTA preparations from E. faecium, E. hirae, and GBS compared with LTA from the homologous vaccine strain E. faecalis 12030. LTA from S. aureus and S. epidermidis was also recognized by the antiserum, but binding was reduced compared with enterococcal LTA. Because variability in the adsorption of different LTAs to the solid phase may have confounded the results mentioned above, an inhibition ELISA with LTA-EF as coating antigen and heterologous LTAs as liquid-phase inhibitors was used for confirmation ( Figure 1B ). Equivalent concentrations of heterologous LTA from E. faecium, E. hirae, and GBS compared with LTA from the vaccine strain were needed to inhibit the binding of antibody to the solid-phase antigen ( Figure 1B ). The discrepancy of E. faecalis 12030 LTA as solid and liquid phase antigen was therefore most likely due to lower adsorption to polystyrene microtiter plates. In contrast, only a maximum of 43% of binding was inhibited by LTA from S. aureus and S. epidermidis, confirming the results obtained by direct ELISA ( Figure 1B) . Minimal binding or inhibition was noted when using an unrelated amphiphilic bacterial antigen (LPS Escherichia coli K-12 W3110) ( Figure 1A and 1B).
Activity and Specificity of Antibodies to Type 1 LTA Against Gram-Positive Bacteria
With evidence that antibodies to E. faecalis LTA also recognized heterologous LTA, we tested their opsonophagocytic activity against other clinically relevant gram-positive bacteria that express type 1 LTA. We evaluated opsonophagocytic killing of bacteria grown to log-phase in the presence of human WBCs, baby rabbit complement, and antibody. Opsonophagocytic killing of E. faecalis 12030 as well as S. aureus Newman occurred in the presence of antisera against E. faecalis LTA, whereas the control immune serum and WBCs plus complement alone did not reduce viable counts (Figure 2A) . Inhibition of anti-LTA antibody with LTA from E. faecalis eliminated killing of E. faecalis in a dose-dependent manner (Figure 2A ).
To define the specificity of opsonic antibodies to type 1 LTA in more detail, 6-to 20-mers of poly-1,3-(glycerolphosphate) were synthesized using a solid-phase synthetic strategy described elsewhere [30] . In brief, teichoic acid oligomers with an aminohexanol spacer were assembled on controlled pore glass using 2-O-benzyl-3-O-dimethoxytrityl glycerol phosphoramidite building blocks for chain elongation and an aminohexanol phosphoramidite as the terminal building block, using a commercially available DNA synthesizer. After cleavage from the solid support, purification, global deprotection of the partially protected teichoic acids, and desalination, the target teichoic acid structures were obtained ( Figure 2C ). The integrity and purity of the compounds was established by 1 H-and 13 C NMR and highresolution mass spectrometry [30] . Preincubation of rabbit antibodies against E. faecalis LTA with the poly-1,3-(glycerolphosphate) 20-mer abolished the opsonophagocytic killing of both E. faecalis and S. aureus (Figure 2A and 2C) . To determine the minimal chain length necessary for the binding of antibodies to type 1 LTA, anti-LTA-EF antiserum was preincubated with the oligomers of different length before measuring opsonophagocytic killing activity against E. faecalis 12030. The potency to inhibit opsonophagocytosis rose in a linear fashion with increasing chain length of the oligomer, reaching 91% for a 20-mer ( Figure 2B ).
Specificity of cross-reactive opsonic antibodies to LTA was further investigated by preincubation of anti-LTA from E. faecalis with a range of heterologous LTAs ( Figure 2D ). Although LTAs from E. faecalis and E. hirae were equally potent in inhibiting opsonophagocytic killing, LTAs from E. faecium, GBS, and staphylococci were less potent but still produced 66%-86% inhibition.
Cross-Reactivity of Opsonic Antibodies to E. faecalis LTA
The activity of anti-LTA antibodies against heterologous bacteria expressing type 1 LTA was investigated by opsonophagocytic killing assay. At a serum dilution of 1:800, .90% of E. faecalis, S. epidermidis, and GBS was killed by anti-LTA-EF ( Figure 3A) . Opsonic killing activity against S. aureus strains was somewhat lower but still reached 63%-83% of the inoculum ( Figure 3A) .
LTA from GBS lacks glycosyl residues and is only (randomly) substituted with D-alanine groups at the C-2 hydroxyl of glycerol. To determine whether this simpler LTA structure is sufficient to raise opsonic antibodies against LTA from other gram-positive bacteria, we vaccinated a rabbit with LTA from GBS NEM 316 (LTA-GBS) and determined opsonophagocytic killing activity of the antiserum ( Figure 3B ). Again, significant opsonic killing was observed not only against the vaccine strain but also against E. faecalis, E. faecium, S. epidermidis, and S. aureus.
Interference in Capsule Expression With Opsonophagocytic Activity of Antibodies Directed Against LTA
Previous studies have demonstrated that capsule expression abolishes opsonization of E. faecalis strains by antibodies directed against LTA [3] . GBS and S. aureus also produce Figure 2 . Specificity of opsonic antibodies to Enterococcus faecalis lipoteichoic acid (LTA). A, Survival of bacteria in the presence of baby rabbit complement, human leukocytes, antibodies, and carbohydrate inhibitors as indicated. Antiserum was used at final dilution of 1:800 (E. faecalis ) and 1:400 (Staphylococcus aureus ), respectively. Antibodies were preincubated for 1 hour at 4°C with the respective inhibitor. Percentage of survival was determined relative to the viable counts in the presence of leukocytes but not complement and antibody. A refers to rabbit antibodies to an alginate-bovine serum albumin conjugate; L refers to rabbit antibodies to LTA from E. faecalis 12030; P100, 20-mer of 1,3-poly(glycerolphosphate) at an inhibitor concentration of 100 lg/mL; L5 to L100, purified LTA from E. faecalis 120303 at 5, 20, and 100 lg/mL, respectively. *P , .0001 vs no inhibitor.
1 P , .001 vs no inhibitor. antiphagocytic polysaccharide capsules, which may mask LTA and prevent binding of antibodies directed against this cell envelope antigen. For both GBS NEM 316 and S. aureus Newman, capsule-deficient mutants were significantly more susceptible to opsonophagocytic killing activity of antibodies against E. faecalis LTA than the respective capsule-expressing wild-type strain, although this effect was more pronounced in GBS ( Figure 4A ). Capsule expression in S. aureus is highly influenced by growth conditions, with little capsular polysaccharide produced during the logarithmic phase of growth and maximal capsule production in the postexponential growth phase [31] . We therefore compared opsonophagocytic killing activity of antibodies to LTA-EF against log-phase and stationary-phase S. aureus Newman ( Figure 4B ). Bacteria grown under conditions that favor capsule expression were less opsonized by anti-LTA EF compared with those grown under conditions that do not support the capsule phenotype.
Protective Efficacy of Antibodies Against E. faecalis LTA in Mice A mouse bacteremia model was used to investigate the protection provided by LTA-specific antibodies against E. faecalis and S. epidermidis. Mice were passively immunized by intraperitoneal injection of 200 lL of immune serum 24 hours prior to infection by intravenous injection of bacteria. Control mice received either normal rabbit serum from infant rabbits or serum of a rabbit immunized against an irrelevant polysaccharide antigen (seaweed alginate, anti-Alg). Mice were killed 24 hours after infection, and bacteria in the blood were enumerated. This time point was chosen because previous studies indicated that E. faecalis bacteremia does not persist for longer than 24 hours in this model [3] . Passive immunization with antibodies against LTA-EF significantly enhanced clearance of E. faecalis and S. epidermidis from the bloodstream ( Figure 5 ). More than 50% of the animals immunized with anti-LTA-EF had cleared E. faecalis and S. epidermidis after 24 hours, whereas all of the control mice were still bacteremic at this time point.
Protection against S. aureus infection was investigated using a previously described mouse peritonitis model [27, 28] . Mice were challenged intraperitoneally with a high dose of 3 different S. aureus strains, and mortality was recorded for 7 consecutive days. Passive immunization with anti-LTA-EF significantly A, Comparative opsonization of capsule-expressing bacteria with the corresponding isogenic capsule-negative strain. Group B streptococci (GBS) NEM 316DcpsD [17] and Staphylococcus aureus NewmanDcap [21] were used as nonencapsulated strains, respectively. Bacteria grown to postexponential phase were opsonized with rabbit antibodies to E. faecalis LTA at a final dilution of 1:200. protected against mortality of S. aureus peritonitis in all strains tested ( Figure 6 ). No significant difference in survival was noted for mice passively immunized with either normal rabbit serum or rabbit antiserum after sham immunization (Figure 6 ), indicating that the vaccination protocol had negligible impact on the protection mediated by the anti-LTA antiserum. Using intravenous challenge with S. aureus Newman (inoculum 1 3 10 8 per mouse) as described above, statistically significant lower bacterial counts were observed in the liver of mice after 48 hours (data not shown).
DISCUSSION
Most vaccines against bacterial pathogens target antigens that are unique to a single species. Here we explore the vaccine potential of LTA because several clinically important gram-positive bacteria express this polymer. It therefore offers the possibility of a single vaccine that is effective against multiple bacterial species. Many nosocomial pathogens, such as staphylococci, enterococci, and some streptococci, express a type 1 LTA with a poly(glycerolphophate) backbone. LTA extends through the peptidoglycan layer, is surface exposed and interacts with abiotic surfaces as well as with host receptors [8, 32, 33] . Compared to other glycopolymers of the bacterial cell envelope, structural variability of LTA is limited. Previous studies have shown that LTA-specific antibodies protect mice against enterococcal bacteremia [2, 3, 12] . Now we extend this work by characterizing cross-reactivity, binding epitopes, and protection mediated by LTA-specific antibodies against a variety of pathogens.
To define the cross-reactivity of antibodies to LTA-EF, we performed binding and inhibition studies using heterologous type 1 LTA that differs from E. faecalis LTA by substitution at the glycerol C-2 hydroxyl and glycolipid anchor structures. Our data indicate that the antibodies induced by vaccination with LTA from E. faecalis are highly crossreactive to LTA from other enterocci, group B streptococci, and, to a lesser degree, to staphylococci. Furthermore, our inhibition studies using nonglycosylated LTA from GBS with a structurally distinct glycolipid anchor suggest that the preponderance of antibodies induced by vaccination . Survival data were compared statistically using the log-rank test.
with E. faecalis LTA are directed against teichoic acid epitopes that do not involve kojibiose. Previous work has shown that vaccination with E. faecalis LTA does not induce antibodies to epitopes containing D-alanine [2] .
Antibodies to E. faecalis LTA opsonized not only different E. faecalis strains but also a range of gram-positive bacteria that express a similar type 1 LTA. Specificity of opsonic antibodies for the poly-1,3-(glycerolphosphate) backbone of LTA was demonstrated by inhibition studies with synthetic teichoic acid oligomers and homologous and heterologous type 1 LTA. These results suggest that poly-1,3-(glycerolphosphate) may be sufficient as a minimal structure for the induction of opsonic antibodies, which would simplify manufacturing of such a vaccine and obviate the need to vaccinate with the complete LTA molecule as a putative ligand for Toll-like receptor 2 [6] .
Some of the bacteria opsonized by anti-LTA express a capsule, which may mask LTA structures on the bacterial cell surface. To some degree, this is reflected by our finding that capsule expression interfered with the opsonphagocytic killing activity of antibodies to E. faecalis against GBS and S. aureus. Somewhat surprisingly, however, even capsule-bearing S. aureus and GBS were partially opsonized by antibodies to LTA. A possible explanation for this observation could be a highly variable capsule production on the intraisolate level [34] , as well as the expression of a microcapsule by S. aureus, which may not fully mask LTA from antibodies [31] . For S. pneumoniae it has also been shown that phosphorylcholin, a molecule directly attached to pneumococcal LTA, is still partially exposed and recognized by opsonic antibodies in encapsulated strains [35, 36] .
Overall, few studies have evaluated the vaccine potential of LTA. One study reported a monoclonal antibody to pneumococcal TA that is opsonic, but no protection studies were performed [37] . The most compelling evidence for LTA as a suitable vaccine antigen comes from studies of antibodies against phosphorylcholin [35] . Goldberg et al [35] demonstrated that antibodies against this LTA-associated molecule opsonize S. pneumoniae and H. influenzae strains and protect against fatal pneumococcal pneumoniae. A humanized mouse chimeric monoclonal immunoglobulin G1 (IgG1) antibody against LTA (pagibaximab) is also in development by the biopharmaceutical company Biosynexus, and data regarding evaluation of this antibody in phase 1/2 trials have been presented [38, 39] . Unfortunately, very limited information on preclinical characterization of this antibody has been published in peer-reviewed journals.
Although the data provided by us hold promise, uncertainties regarding the biologic role of LTA-specific antibodies remain. For example, if naturally acquired antibodies against LTA are present in humans, as suggested by a previous report, why are humans susceptible to pathogens that express type 1 LTA [40] ? Possible explanations for this discrepancy could include individual variation in IgG isotype [35] , differences in affinity or avidity [41] , or fine specificity of naturally acquired antibodies [42, 43] .
Because enterococci and other gram-positive commensals of the gastrointenstinal tract also express LTA, vaccine strategies using this antigen may need to overcome reduced immunogenicity due to B-cell hyporesponsiveness [44] and immunotolerance [45, 46] . However, previous exposure to polyribosyl-ribitol-phosphate of H. influenzaeda vaccine antigen chemically closely related to LTAddoes not lead to hyporesponsiveness. In addition, hyporesponsivness may at least partially be overcome by conjugate vaccines [47] .
In summary, our data indicate that antibodies elicited by vaccination with E. faecalis-LTA are cross-reactive with LTA from other enterococcal, streptococcal, and staphyloccocal species and bind predominately to poly-1,3-(glycerolphosphate). LTAspecific antibodies are opsonic in vitro, promote the clearance of E. faecalis and S. epidermidis from the bloodstream, and protect against infection with S. aureus, including methicillin-resistant S. aureus. Our data suggest that an LTAbased vaccine has the potential to protect against some of the most important gram-positive nosocomial pathogens.
Notes
After submission of this manuscript, results of a phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of pagibaximab in very low birth weight neonates have been published [48] . The study failed to meet its primary endpoint (number of patients with staphylococcal sepsis days 0-35). However, none of the infants who received the higher dose of pagibaximab developed Gram-positive sepsis (staphylococcal and non-staphlyococcal).
